Gold prices steady as traders assess Fed rate outlook after soft US data
Janac K. Charles, the President and CEO of Arteris , Inc. (NASDAQ:AIP), recently sold a portion of his holdings in the company. According to a recent SEC filing, Charles sold 1,330 shares of common stock on March 3, 2025, at an average price of $8.3833 per share, amounting to a total transaction value of approximately $11,149. The transaction comes as the stock has declined over 10% in the past week, though InvestingPro data shows the company maintains impressive gross profit margins of nearly 90%.
Following this sale, Charles retains direct ownership of 327,240 shares. Additionally, he holds indirect ownership of 9,907,691 shares through Bayview Legacy, LLC, where he has voting and dispositive power, and 56,252 shares through the Charles and Lydia Janac Trust, for which he serves as trustee. The shares sold were to satisfy tax liabilities arising from the release of restricted stock units. Analysts remain optimistic about the company’s prospects, with price targets ranging from $11 to $16 per share. For deeper insights into insider trading patterns and comprehensive analysis, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Arteris, Inc. has been the focus of analyst attention with notable developments affecting its financial outlook. Jefferies analyst Blayne Curtis raised the company’s price target to $11.00 from $7.00, maintaining a Hold rating. This adjustment reflects Arteris’ progress in the microcontroller unit (MCU) market and the introduction of the FlexGen solution, which is expected to boost average selling prices by 30%. Despite these advances, Jefferies remains cautious due to lower-than-expected 2025 guidance, seeking more evidence of improved execution before changing its stance.
Meanwhile, Northland analysts increased their price target for Arteris to $16.00, up from $14.00, while reaffirming an Outperform rating. They noted that Arteris’ revenue met expectations, with bookings reaching approximately $33.6 million, resulting in a book-to-bill ratio of 2.2:1. The success of the FlexNoC 5 product and the introduction of FlexGen, which is being evaluated by 13 customers, were key factors in the revised price target. Northland expressed confidence in Arteris’ market position and the potential positive impact of FlexGen on future revenue growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.